# FDA 483 - Zhehai Wang - October 18, 2021

Source: https://www.globalkeysolutions.net/records/483/zhehai-wang/d82ee499-f371-4126-bdf5-2a32eb233e3b

> FDA 483 for Zhehai Wang on October 18, 2021. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Zhehai Wang
- Inspection Date: 2021-10-18
- Product Type: drugs
- Office Name: Beijing China District Office
- Summary: An FDA inspection of Zhehai Wang, a clinical investigator in Jinan, China, revealed a significant issue regarding the conduct of an investigation. The firm failed to conduct an investigation in accordance with the signed statement of investigator and investigational plan. This indicates a serious deviation from protocol requirements for clinical trials.

## Related Officers

- [Marijo B. Kambere](https://www.globalkeysolutions.net/people/marijo-b-kambere/54e010f0-0d56-4b20-b5e2-112e372de58b)

Company: https://www.globalkeysolutions.net/companies/zhehai-wang/6dd9fcda-2328-405b-8749-6b3c8bb115c8

Office: https://www.globalkeysolutions.net/offices/beijing-china-district-office/ef48e02a-2aae-4b30-8893-272da5f8b9d8